This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GRTS Gritstone bio (GRTS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Gritstone bio Stock (NASDAQ:GRTS) 30 days 90 days 365 days Advanced Chart Get Gritstone bio alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.03▼$0.6352-Week Range N/AVolume61.02 million shsAverage Volume7.01 million shsMarket Capitalization$3.50 millionP/E RatioN/ADividend YieldN/APrice Target$2.17Consensus RatingModerate Buy Company Overview Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. Read More Receive GRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTS Stock News HeadlinesGritstone Bio sets sale of assets through Bankruptcy CourtDecember 13, 2024 | bizjournals.comGritstone Oncology Inc (GRTSQ)November 27, 2024 | investing.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 12 at 2:00 AM | Crypto Swap Profits (Ad)Gritstone bio, Inc. (GRTSQ)November 22, 2024 | finance.yahoo.comFirm Retention Summary: Gritstone bioNovember 20, 2024 | wsj.comGritstone’s bankruptcy filing reveals biotech’s tough choicesOctober 14, 2024 | bizjournals.comGritstone Oncology Pursues Restructuring Through Chapter 11October 11, 2024 | finance.yahoo.comWhy Gritstone Bio (GRTS) Stock Is Down 64% TodayOctober 11, 2024 | benzinga.comSee More Headlines GRTS Stock Analysis - Frequently Asked Questions How were Gritstone bio's earnings last quarter? Gritstone bio, Inc. (NASDAQ:GRTS) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.12. The business had revenue of $0.92 million for the quarter, compared to analysts' expectations of $2.77 million. Gritstone bio had a negative net margin of 910.50% and a negative trailing twelve-month return on equity of 328.51%. When did Gritstone bio IPO? Gritstone bio (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Gritstone bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), American Water Works (AWK) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2024Today7/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRTS CIK1656634 Webwww.gritstoneoncology.com Phone(510) 871-6100FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Price Target for Gritstone bio$2.17 High Price Target$5.00 Low Price Target$0.50 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$138.49 million Net Margins-910.50% Pretax Margin-910.50% Return on Equity-328.51% Return on Assets-82.53% Debt Debt-to-Equity Ratio1.83 Current Ratio2.54 Quick Ratio2.54 Sales & Book Value Annual Sales$496 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / BookN/AMiscellaneous Outstanding Shares108,569,000Free Float111,837,000Market Cap$3.50 million OptionableOptionable Beta0.49 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:GRTS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gritstone bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gritstone bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.